Close

Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment

Go back to Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment
(AMEX: CLABD) Delayed: 4.35 --0 (-0%)
Previous Close $4.35    52 Week High
Open $2.77    52 Week Low
Day High $4.35    P/E N/A 
Day Low $4.35    EPS
Volume 23,412       

Majesco Entertainment Company (NASDAQ: COOL) Delayed: 11.00 +0.01 (0.09%)
Previous Close $10.99    52 Week High $4.10 
Open $10.99    52 Week Low $0.61 
Day High $11.00    P/E N/A 
Day Low $10.99    EPS $-0.30 
Volume 1,039